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Abstract
Objectives:To evaluate the 52-week safety/tolerability of oral olanzapine for adolescents with schizophrenia or bipolar mania
and compare effectiveness of a standard versus intense behavioral weight intervention in mitigating risk of weight gain.
Methods:Patients 13–17 years old with schizophrenia (Brief Psychiatric Rating Scale for Children [BPRS-C] total score>30;
item score ‡3 for hallucinations, delusions, or peculiar fantasies) or bipolar I disorder (manic or mixed episode; Young Mania
Rating Scale [YMRS] total score ‡15) received open-label olanzapine (2.5–20 mg/day) and were randomized to standard
(n = 102; a single weight counseling session) or intense (n = 101; weight counseling at each study visit) weight intervention.
The primary outcome measure was mean change in body mass index (BMI) from baseline to 52 weeks using mixed-model
repeated measures. Symptomatology was also assessed.
Results: No statistically significant differences between groups were observed in mean baseline-to-52-week change in BMI
(standard: +3.6 kg/m2; intense: +2.8 kg/m2; p = 0.150) or weight (standard: +12.1 kg; intense: +9.6 kg; p = 0.148). Percentage
of patients at endpoint who had gained ‡15% of their baseline weight was 40% for the standard group and 31% for the intense
group ( p = 0.187). Safety/tolerability results were generally consistent with those of previous olanzapine studies in ado-
lescents, with the most notable exception being the finding of a mean decrease in prolactin. On symptomatology measures,
patients with schizophrenia had a mean baseline-to-52-week change in BPRS-C of -32.5 (standard deviation [SD] = 10.8),
and patients with bipolar disorder had a mean change in YMRS of-16.7 (SD = 8.9), with clinically and statistically significant
improvement starting at 3–4 days for each.
Conclusions: Long-term weight gain was high in both groups, with no statistically significant differences between the
standard or intense behavioral weight interventions in BMI or weight. Safety, tolerability, and effectiveness findings were
generally consistent with the known profile of olanzapine in adolescents.
Keywords: olanzapine, adolescent, weight management, schizophrenia, bipolar, counseling
Introduction
Schizophrenia and bipolar disorder are serious and generallylifelong disorders that often begin during adolescence (American
Psychiatric Association 2000). It is estimated that 39% of men with
schizophrenia and 23% of women with schizophrenia experience
onset of the illness before age 19 years (Loranger 1984); peak age of
onset of first symptoms of bipolar disorder is reported to occur be-
tween age 15 and 19 years (Bauer and Pfennig 2005). Childhood
onset (by age 12 years) of these disorders is less common but is often
associated with greater severity of illness (McClellan et al. 1993;
Strober et al. 1995; Wozniak et al. 1995; Hollis 2000; Kumra et al.
2001; Remschmidt and Theisen 2012). In both disorders, early and
effective treatments may improve the long-term outcomes (Tohen
1997; Hollis 2000; Post et al. 2010).
Second-generation antipsychotics are effective and commonly
used to treat schizophrenia and bipolar mania in adults and adoles-
cents. Weight gain and other adverse metabolic changes often ac-
company treatment with second-generation antipsychotics (Moreno
et al. 2010; Correll et al. 2011; Datta et al. 2014). Such metabolic
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changes not only may be of concern due to the potential long-term
health risk to the patient but also can be a significant potential ob-
stacle to patients (or their parents) agreeing to start such a treatment or
practice medication adherence (Weiden et al. 2004). Compounding
the treatment-emergent weight gain in adolescents with bipolar dis-
order are poorer nutritional behaviors due to stress-induced eating
(Martin et al. 2016) and lower levels of physical activity (Jewell et al.
2015) in this patient population compared with control groups.
Strategies recommended for preventing or ameliorating weight
gain in children and adolescents treated with second-generation
antipsychotics include controlling the environment, monitoring
behavior, setting goals, rewarding successful behaviors, identifying
and solving problems, and adapting parental skills (Correll and
Carlson 2006). Goldstein et al. (2011) developed a brief motiva-
tional intervention for preventing treatment-emergent weight gain
among youth with bipolar disorder.
Olanzapine is a second-generation antipsychotic that has dem-
onstrated efficacy in adolescents with schizophrenia (Kryzha-
novskaya et al. 2009a) and adolescents with manic or mixed episodes
of bipolar disorder (Tohen et al. 2007). Results from these studies also
indicated clinically significant weight gain and metabolic changes
after 3 weeks (Tohen et al. 2007) and 6 weeks (Kryzhanovskaya et al.
2009a) of randomized, double-blind treatment with olanzapine rel-
ative to placebo, with continued changes up to 26 additional weeks of
open-label treatment (McCormack 2010). Pooled safety results from
the adolescent olanzapine trials (Kryzhanovskaya et al. 2009b) in-
dicated similar types of adverse events as seen in adults treated with
olanzapine. In contrast to previous observations in adults, adolescent
patients were found to have a greater magnitude and incidence of
weight gain, as well as greater changes in lipids (specifically total
cholesterol, low-density lipoprotein cholesterol, and triglycerides),
hepatic enzymes, prolactin, and sedation (Kryzhanovskaya et al.
2012; Eli Lilly and Company 2013).
These findings may be of concern for many clinicians when
evaluating how best to manage serious mental illness in this vul-
nerable adolescent population. Clinicians should consider the po-
tential long-term risks when treating adolescents with olanzapine
and whether some of these risks can be proactively mitigated.
Current guidance on treating with a second-generation antipsy-
chotic includes educating patients on a healthy lifestyle and the need
to reduce caloric intake and to increase exercise (Citrome et al.
2005; Tschoner et al. 2007). Some evidence supports the effec-
tiveness of these methods in adults (Faulkner et al. 2007; Pendle-
bury et al. 2007; Alvarez-Jimenez et al. 2008; Holt et al. 2010), but
few studies have evaluated such methods specifically in adolescents
treated with second-generation antipsychotics.
The current study was conducted at the request of the U.S. Food
and Drug Administration as a condition of approval of olanzapine
for use in adolescents with schizophrenia or bipolar I disorder
(manic or mixed episodes). The primary objective of the study was
twofold: (1) to evaluate the longer term safety and tolerability of
olanzapine in this population and (2) to evaluate whether an intense
behavioral weight intervention would be superior to a standard
behavioral weight intervention in the mitigation of weight gain in
adolescent patients treated with olanzapine as measured by overall
mean change from baseline in body mass index (BMI).
Methods
Patient selection
Patients were inpatients or outpatients, aged 13–17 years, and
diagnosed with schizophrenia or bipolar I disorder (manic or mixed
episode) according to the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
(American Psychiatric Association 2000) and as confirmed by
the Kiddie Schedule for Affective Disorders and Schizophrenia
for School Aged Children-Present and Lifetime (K-SADS-PL)
(Kaufman et al. 1997). Patients with schizophrenia had a Brief
Psychiatric Rating Scale for Children (BPRS-C) (Overall and
Pfefferbaum 1982) total score of >30, with an item score ‡3 for
hallucinations, delusions, or peculiar fantasies at screening and
randomization. Patients with bipolar I disorder had a Young Mania
Rating Scale (YMRS) (Young et al. 1978) total score of ‡15 at
screening and randomization.
Patients were excluded if they had an acute, serious, or unstable
medical condition; a history of mental retardation; a current diag-
nosis of autism or pervasive developmental disorder; a diagnosis of
substance dependence other than nicotine or caffeine within 30 days
before study entry; or were judged to be at risk for suicide. Patients
were also excluded if they were receiving pharmaceutical treatment
for weight management or were participating in a structured behav-
ioral diet and/or exercise weight loss program. Patients should not
have received olanzapine for ‡5 days during the month before
screening and could not have a history of allergic reaction or inability
to tolerate or respond to olanzapine.
Study design
This was a phase 4, single-drug arm, open-label, safety and
tolerability study of oral olanzapine with a randomized, unblinded
behavioral weight intervention conducted between September 2009
and May 2013 at 29 centers in the United States, Russia, Poland,
and Germany. Before patient enrollment, the appropriate institu-
tional review boards evaluated and approved the study protocol.
Written informed assent and consent were obtained from each
patient and his or her legal guardian, respectively, at study entry
and before commencement of any study procedures. The study was
conducted in full accordance with ethical principles of Good
Clinical Practice (GCP) (Fromell 2008) and the Declaration of
Helsinki and its guidelines (Parsa-Parsi et al. 2014).
On enrollment, patients entered a 2- to 14-day screening and
washout period during which all antipsychotic, anticonvulsant, and
mood stabilizing medications had to be discontinued at least 2 days
before entry into the open-label treatment period. Eligible patients
then entered a 52-week open-label treatment period and were initi-
ated on oral olanzapine at a starting dose of 2.5 or 5 mg/day based on
initial patient assessment and at the discretion of the investigator.
Dosing thereafter was flexible within a range of 2.5–20 mg/day, with
dose changes allowed in 2.5 or 5 mg increments as needed. No ad-
junctive antipsychotics, mood stabilizers, anticonvulsants, or medi-
cations prescribed specifically for weight management were allowed
during the study. Psychostimulants or medications with potential
weight-altering effects were allowed only if the patient had been on a
stable dose for at least 2 weeks before study enrollment and if pre-
scribed for use other than for weight management.
Patients were seen twice in week 1, then weekly through week 4,
every 2 weeks through week 8, and then every 4 weeks through week
52. Effectiveness, safety, and tolerability were assessed at each visit.
On entry into the open-label olanzapine treatment period, pa-
tients were randomized in a 1:1 ratio into two weight intervention
groups, a standard behavioral weight counseling intervention
(standard group) or an intense behavioral weight counseling in-
tervention (intense group). The standard intervention consisted of a
single counseling session only at time of randomization for both the
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patient and the patient’s parent/guardian. This session was at least
15 minutes in duration (with no maximum time limit), during which
time the participants received basic information on healthy eating
and exercise habits. The intense intervention consisted of coun-
seling sessions of at least 15-minute duration at every study visit for
both the patient and the parent/guardian.
Counseling sessions were led by clinical site personnel who had
been trained on the intervention program, and it was recommended
that sites use the same counselor for the patient from visit to visit.
Each counseling session included discussion of prespecified in-
formation and handouts on healthy eating (food selection) and/or
healthy exercise (physical activity) habits, with different topics and
guidance covered at each visit, adapted from the Smart Moves
weight management program (Savoye et al. 2007).
Both participants and parents/guardians in the intense group were
introduced to ‘‘lifestyle logs’’ (food and exercise logs for recording
daily physical activity and food/beverage intake) and received
training on the importance of healthy food choices, portion control, a
balanced diet, and regular exercise, as well as education about nu-
trition, calories, and metabolism. Participants in the intense inter-
vention also received a pedometer to encourage exercise and
tracking of exercise. Each session included review of patient eating
and exercise habits since the last visit and potential introduction of
behavior modification strategies (such as goal setting and strategies
for overcoming barriers to success). Counselors were asked to focus
on and help participants identify positive behaviors in the lifestyle
logs to encourage further positive behaviors. Counseling sessions
thus included a combination of education, problem solving, and
motivational enhancement in a family counseling setting.
Patients in the intense group who met criteria for obesity or had a
significant weight increase (defined as BMI ‡97th percentile at
baseline or at two or more successive visits or a BMI increase of
‡0.5 U at two or more successive visits) received additional tools
and guidance to encourage weight reduction, including a bathroom
scale for self-monitoring of weight at home and instruction on
logging caloric intake and strategies to reduce caloric intake. Par-
ticipant food and exercise logs were expanded to track feelings and
environmental situations tied to eating. Sessions then focused on
identifying behavioral patterns and triggers for overeating and
developing solutions to avoid and manage such triggers. Partici-
pants’ lifestyle log entries were not collected or analyzed as part of
the study but were used solely as a counseling tool.
Measures
The primary measure of effectiveness of the behavioral weight
interventions was mean change in BMI. Weight and waist cir-
cumference were also assessed. In addition to the weight-related
assessments, the overall safety and tolerability of oral olanzapine
were evaluated through the collection of vital signs, adverse events,
laboratory analytes, electrocardiogram (ECG) recordings; the as-
sessment of extrapyramidal symptoms (EPS) using the Abnormal
Involuntary Movement Scale (AIMS) (Guy 1976), the Barnes
Akathisia Global Score (Barnes 1989), and the Simpson–Angus
Total Score (SAS) (Simpson and Angus 1970); and the assessment
of suicidality using the Columbia Suicide Severity Rating Scale
(C-SSRS) (Posner 2007; Posner et al. 2011). The effectiveness of
olanzapine in the treatment of schizophrenia or bipolar mania was
assessed using the BPRS-C (Lachar et al. 2001) or YMRS (Young
et al. 1978), respectively. All patients’ symptom severity was as-
sessed using the Clinical Global Impression–Severity (CGI-S)
scale (Guy 1976).
Patient BMI was also analyzed categorically based on the World
Health Organization (World Health Organization 2007) pediatric
BMI growth charts (2007) by age and gender, with shifts in BMI
categories analyzed using percentile cutoffs for underweight (<5th
percentile), healthy weight (‡5th to <85th percentile), overweight
(‡85th to <95th percentile), and obese (‡95th percentile).
Statistical analyses
Analyses were conducted on all randomized patients who re-
ceived at least 1 dose of study medication. Mean changes for BMI
(primary endpoint) were assessed using a mixed model repeated
measures (MMRM) analysis, which included the model terms of
intervention group, region, visit, intervention group-by-visit inter-
action, baseline BMI, baseline age, and gender. Mean changes in
other continuous variables were assessed using MMRM analyses,
as well as last observation carried forward (LOCF) analyses, with
LOCF intervention group comparisons based on analysis of co-
variance models; all models varied but included terms for inter-
vention group and baseline.
For comparison of categorical variables, a Fisher’s exact test was
used. Subgroup analyses were conducted for selected categorical and
continuous safety measures, including mean change from baseline in
BMI and weight and incidence of specific treatment-emergent ad-
verse events of interest (e.g., ‘‘weight increased’’). Subgroups in-
cluded gender (male or female), disease state (schizophrenia or
bipolar disorder), race (white or non-white), and geographic region
(US or non-US). Continuous outcomes were assessed using an
MMRM model similar to that used for the primary outcome analysis,
including the terms for baseline, intervention groups, region (if re-
gion was not a subgroup variable), subgroup, visit-by-intervention
interaction, and the intervention-by-subgroup interaction. The Mantel–
Haenszel common-odds ratio and the Breslow–Day test for homoge-
neity of odds ratio were used to evaluate differences across the subsets
for dichotomous categorical outcomes.
All tests of hypotheses were two sided with a type I error of 0.05.
No adjustments for multiple testing were made; only the primary
BMI analysis could be considered confirmatory.
Results
Patient disposition and characteristics
A total of 203 patients were randomized and received the study
drug (standard group n= 102; intense group n= 101) (Fig. 1). Of
these, 82 patients (40.4%) completed the study (standard group
n = 45 [44.1%]; intense group n= 37 [36.6%]), with no significant
difference between intervention groups regarding study completion
or reasons for discontinuation. Median time to all-cause discon-
tinuation was 238 days for the standard group and 211 days for the
intense group ( p = 0.445), with an estimated 6-month discontinu-
ation rate of 47.1% for the standard group and 45.5% for the intense
group. Adverse events were the most frequent reason for study
discontinuation (standard group, n = 19 [18.6%]; intense group,
n = 15 [14.9%]). Adverse events that lead to study discontinuation
in more than one patient per weight intervention group were weight
increase (standard group, n = 8 [7.8%]; intense group, n= 6 [5.9%])
and abnormal liver function (standard group, n= 2 [2.0%]; intense
group, n = 0).
Patient characteristics at baseline are presented in Table 1 for the
total group of patients, as well as by disease state and by ran-
domized weight intervention group. Patients had a mean age of 15.8
years, were predominantly white (80.8%), and had a roughly equal
924 DETKE ET AL.
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FIG. 1. Patient disposition. Note: Explanations for ‘‘Withdrawal by Subject’’ were as follows. Standard group: no additional com-
ments provided (n= 3), change of residence (n = 2), excessive weight gain (n= 2), desire to start different medication (n= 1), lack of
interest (n = 1), thinks to be cured (n = 1), refusal to follow protocol procedures (n= 1). Intense group: no additional comments provided
(n = 4), desire to start different medication (n= 2), unhappy with medication (n = 1), lack of effect (n= 1), weight gain (n= 1), behavioral
issues (n = 1), does not want to participate due to bloodwork (n = 1), unable to go to study visits (n= 1), change of residence (n= 1),
thinks to be cured (n= 1).
Table 1. Baseline Demographic and Illness Characteristics by Disease State and by Weight Intervention Group
Variable
All
patients
(N = 203)
Bipolar I
disorder
(n= 116)
Schizophrenia
(n = 87)
Standard
group
(n= 102)
Intense
group
(n = 101)
Age (years), mean (SD) 15.8 (1.5) 15.4 (1.5) 16.3 (1.4) 15.9 (1.5) 15.7 (1.5)
Male, n (%) 106 (52.2) 51 (44.0) 55 (63.2) 52 (51.0) 54 (53.5)
Hispanic or Latino ethnicity, n (%) 24 (11.8) 21 (18.1) 3 (3.4) 15 (14.7) 9 (8.9)
Race, n (%)
American Indian or Alaska Native 1 (0.5) 0 1 (1.1) 0 1 (1.0)
Asian 3 (1.5) 3 (2.6) 0 2 (2.0) 1 (1.0)
Black or African American 26 (12.8) 19 (16.4) 7 (8.0) 12 (11.8) 14 (13.9)
Multiple 9 (4.4) 9 (7.8) 0 4 (3.9) 5 (5.0)
White 164 (80.8) 85 (73.3) 79 (90.8) 84 (82.4) 80 (79.2)
Country of origin, n (%)
Germany 3 (1.5) 0 3 (3.4) 2 (2.0) 1 (1.0)
Poland 18 (8.9) 3 (2.6) 15 (17.2) 6 (5.9) 12 (11.9)
Russian Federation 55 (27.1) 2 (1.7) 53 (60.9) 28 (27.5) 27 (26.7)
United States 127 (62.6) 111 (95.7) 16 (18.4) 66 (64.7) 61 (60.4)
BMI (kg/m2), mean (SD) 24.0 (5.7) 25.2 (6.4) 22.3 (4.1) 24.6 (6.0) 23.3 (5.4)
Weight (kg), mean (SD) 67.5 (18.5) 69.6 (20.9) 64.6 (14.2) 70.2 (20.1) 64.7 (16.3)
Waist circumference (cm), mean (SD) 82.9 (15.2) 86.3 (17.3) 78.4 (10.3) 85.5 (16.1) 80.2 (13.8)
Family history of obesity (first-degree
relative), n (%)
62 (30.5) 54 (46.6) 8 (9.2) 33 (32.4) 29 (28.7)
YMRS total score, mean (SD) NA 23.2 (6.4) NA 23.1 (6.9)a 23.3 (5.8)b
BPRS-C total score, mean (SD) NA NA 45.4 (10.1) 44.2 (10.3)c 46.6 (9.8)d
CGI-S total score, mean (SD) 4.5 (0.7) 4.4 (0.6) 4.7 (0.7) 4.5 (0.7) 4.5 (0.6)
Hospitalized during prior 12 months, n (%) 106 (52.2) 53 (45.7) 53 (60.9) 51 (50) 55 (54.5)
an = 58.
bn= 58.
cn = 44.
dn= 43.
BMI, body mass index; BPRS-C, Brief Psychiatric Rating Scale for Children; CGI-S, Clinical Global Impression–Severity; NA, not applicable;
SD, standard deviation; YMRS, Young Mania Rating Scale.
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gender distribution (male= 52.2%). A total of 87 patients (42.9%)
were diagnosed with schizophrenia (standard group, n= 44; intense
group, n= 43), and 116 patients (57.1%) were diagnosed with bipolar
I disorder (n= 58 for both groups), with the majority of patients with
bipolar disorder coming from the United States and the majority of
patients with schizophrenia coming from Russia. Across all patients,
mean CGI-S score at baseline was 4.5, indicating a moderately to
markedly ill population. For the patients with schizophrenia, baseline
BPRS-C total score was 45.4, indicating an acutely psychotic pop-
ulation. For the patients with bipolar disorder, baseline YMRS total
score was 23.2, indicating an acutely manic population.
Comparison of weight intervention groups indicated some sig-
nificant differences at baseline; patients in the standard group had a
mean weight*5 kg heavier than the intense group (standard group,
70.2 kg [standard deviation, SD= 20.1]; intense group, 64.7 kg
[16.3]) and a mean waist circumference *5 cm wider (standard
group, 85.5 cm [SD = 16.1]; intense group 80.2 cm [13.8]).
Median duration of exposure to olanzapine during the study was
219 days, with a mean daily dose of 10.75 mg (SD=5.08) and a
median modal daily dose of 10 mg. No significant differences between
weight intervention groups were observed with regard to drug expo-
sure or dosing (standard group, median exposure=226 days, mean
daily dose=10.52 mg [SD=5.04]; intense group, median expo-
sure=219 days, mean daily dose=10.98 mg [SD=5.13]).
Effectiveness of weight interventions
No statistically significant differences between the standard and
the intense groups were observed in overall mean change in BMI
( p= 0.134) or in least squares (LS) mean change in BMI at any study
visit (Fig. 2a). LS mean change in BMI from baseline to 52 weeks
was 3.64 kg/m2 (standard error [SE]= 0.39) for the standard group
and 2.83 kg/m2 (SE= 0.40) for the intense group ( p= 0.150). Base-
line to LOCF endpoint evaluation of mean changes in patients treated
for at least 6 months also did not result in statistically significant
differences between weight intervention groups in increases in BMI
(standard group, 3.36 kg/m2 [SE= 0.41]; intense group 2.99 kg/m2
[0.40]; p= 0.520). Distribution of changes in BMI (Fig. 2b) indicated
that a majority of patients (standard group, 82%; intense group, 75%)
had greater increases than would be expected through normal ado-
lescent growth (i.e., greater than approximately half a unit of BMI
per year). However, there were some patients whose BMI stayed the
same or decreased (standard group, 9%; intense group, 15%).
There were no significant differences between weight inter-
ventions with regard to mean change in bodyweight (Fig. 2c), and
both weight intervention groups showed clinically significant
mean increases in weight throughout the study (all within-group
p-values <0.001). From baseline to 52 weeks, patients experienced
an LS mean change in weight of 12.05 kg (SE= 1.16) in the stan-
dard group and 9.63 kg (SE= 1.20) in the intense group ( p= 0.148).
Among patients treated for at least 6 months, mean change in
weight from baseline to LOCF endpoint was also high but with no
significant difference between intervention groups (standard group,
10.97 kg [SE= 1.21]; intense group, 9.82 kg [1.19]; p = 0.495).
A majority of patients in both intervention groups gained ‡7% of
their baseline weight at endpoint (Fig. 3): 56.9% in the standard
group and 63.4% in the intense group. No significant differences
were observed between the weight intervention groups at any time
or at endpoint for any categories of potentially clinically significant
weight changes, although there was a numeric trend at the higher
degrees of weight gain, with numerically fewer patients in the in-
tense group gaining ‡15% or ‡25% of their baseline bodyweight at
any time or at endpoint than in the standard group. For example, the
percentage of patients at endpoint who gained ‡15% of their
baseline weight was 40% for the standard group and 31% for the
intense group ( p= 0.187).
There were no significant differences between interventions with
regard to mean change in waist circumference. From baseline to 52
weeks, LS mean change in waist circumference was 7.2 cm (SE=1.1)
in the standard group and 7.3 cm (SE=1.1) in the intense group
( p=0.954).
Subgroup analyses were conducted to examine whether the
weight interventions had differential effects on BMI or weight
based on gender, disease state, race, or geographical region. No
statistically significant intervention effect was found within any of
the subgroups on either measure, and there were no statistically
significant interactions between any subgroups and the interven-
tion. However, a statistically significant difference was noted be-
tween boys and girls with respect to the relationship between
weight intervention and the adverse event of ‘‘increased weight’’
( p= 0.028); male patients in the standard group were somewhat
less likely to have weight increase reported as an adverse event than
those in the intense group (15% vs. 20%), whereas female patients
in the standard group were more likely to have weight increase
reported as an adverse event than those in the intense group (46%
vs. 21%). This finding would appear to suggest that female patients
were more likely to benefit from the intense weight intervention
program than were male patients. There was also some evidence
with respect to the disease state groups ( p = 0.066); patients with
schizophrenia in the standard group were somewhat less likely to
experience increased weight than those in the intense group (11%
vs. 16%), whereas patients with bipolar disorder in the standard
group were more likely to experience increased weight than those
in the intense group (45% vs. 24%). These two findings are likely
confounded as there were more male patients with schizophrenia.
Treatment effectiveness
Across all patients, all disease state effectiveness measures dem-
onstrated significant mean improvement at 3–4 days and at all sub-
sequent visits, with improvement increasing throughout the trial
(Figs. 4, and 5a, b). Patients with bipolar disorder in the intense group
showed less improvement than in the standard group on both the
YMRS (overall p=0.018) and the CGI-S (overall p= 0.016). There
was no such interaction between disease state effectiveness and
weight intervention among the patients with schizophrenia.
Safety and tolerability
Adverse events. A total of 162 patients (79.8%) experienced
at least one treatment-emergent adverse event during the study
(Table 2). The most frequently reported adverse events were weight
increase, somnolence, and headache, with no significant differences
between weight intervention groups. Weight increase was reported
as an adverse event in 30.4% of patients in the standard group and
20.8% of patients in the intense group ( p= 0.148). A total of 33
(16.3%) patients experienced serious adverse events (SAEs) (stan-
dard group, 12.7%; intense group, 19.8%; p= 0.188), with most
events being related to disease state. The SAEs occurring in more
than one patient in the standard group were suicidal ideation (three
patients [2.9%]) and suicide attempt (two patients [2.0%]). The
SAEs occurring in more than one patient in the intense group were
psychotic disorder (four patients [4.0%]), suicidal ideation (two
patients [2.0%]), and bipolar disorder/bipolar I disorder (six patients
[5.9%]). Only the SAE rate of bipolar disorder/bipolar I disorder was
926 DETKE ET AL.
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significantly different between intervention groups ( p= 0.014). All
other SAEs were reported by one patient each and were mostly
disease state related, with a notable exception of a single case of
neuroleptic malignant syndrome. No deaths occurred.
Laboratory analytes. No significant differences between
weight intervention groups were observed with regard to mean
changes from baseline to LOCF endpoint in any laboratory analytes
(Table 3). Figure 6 presents mean changes in the total group of
patients over time in select analytes using MMRM methodology.
Mean prolactin levels for the total group of patients indicated a
transient increase at week 6 but a subsequent decrease below
baseline starting at week 16 through week 52. A transient increase
early in treatment was also noted for alanine aminotransferase.
Categorical changes in metabolic analytes and prolactin at any time
and at endpoint are presented in Figure 7.
ECG and vital signs. Patients in the standard group experi-
enced a significantly greater LS mean increase from baseline in
heart rate compared with patients in the intense group ( p< 0.001;
Table 3). There was no significant difference between intervention
groups in Fridericia-corrected QT interval (QTcF). No patients
experienced a QTcF ‡450 milliseconds at any time, and no patients
experienced an increase in QTcF ‡60 milliseconds at any time.
Patients in the standard group showed clinically small mean in-
creases in blood pressure (statistically significant differences from
intense group for supine diastolic [p= 0.017] and standing systolic
[p = 0.031] blood pressure), whereas patients in the intense group
demonstrated little to no mean change (Table 3).
Extrapyramidal symptoms. Mean baseline scores for all
three indices of EPS were low. Postbaseline mean changes were
small and not clinically significant. Among the total group of
FIG. 2. (a) LS mean changes in BMI over time for patients receiving a standard or intense behavioral weight counseling intervention
(MMRM analysis). (b) Percentage of patients experiencing change from baseline to LOCF endpoint in BMI for patients receiving a
standard or intense behavioral weight counseling intervention. (c) LS mean changes in weight over time for patients receiving a standard
or intense behavioral weight counseling intervention (MMRM analysis). BMI, body mass index; LOCF, last observation carried
forward; LS, least squares; MMRM, mixed model repeated measures; N, number of patients. Error bars indicate standard error.
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patients, the incidences of treatment-emergent akathisia (score of
‡2 in patients who had a score of <2 at baseline on the Barnes
Akathisia Scale), parkinsonism (score of >3 in patients who had a
score of £3 at baseline on the SAS), and dyskinesia (AIMS single
items score of ‡3, or ‡2 item scores ‡2 with all single item scores
<3 and ‡6 item scores <2 at baseline) were 8.9%, 5.8%, and 1.1%,
respectively, at any time, and 3.4%, 2.6%, and 1.1%, respectively,
at endpoint. No significant differences between weight intervention
groups for any of these treatment-emergent events were observed.
Suicidality. Based on the C-SSRS, 27 patients (13.3%) dis-
played suicidal ideation during the study (standard group, 17.6%;
intense group, 8.9%), and 6 patients (3.0%) exhibited suicidal be-
havior (standard group, 4.9%; intense group, 1.0%). No completed
suicides occurred.
Discussion
This study evaluated the 1-year safety and tolerability of olan-
zapine (2.5–20 mg/day) in adolescent patients with schizophrenia
or bipolar I disorder with manic or mixed episodes. The study also
evaluated the effectiveness of an intense behavioral weight inter-
vention (consisting of regular diet and lifestyle counseling sessions)
to see whether such an intervention would be superior to a standard
behavioral weight counseling intervention (consisting of a single
counseling session) with respect to mitigation of weight gain.
Behavioral weight counseling intervention
Results indicated that patients in both groups gained a substan-
tial amount of weight over the course of 1 year, with a majority of
patients gaining ‡7% of their baseline weight. Patients randomized
to the intense intervention had, on average, numerically smaller
changes on weight-related measures (LS mean changes in BMI and
weight; categorical changes in BMI and weight; treatment-emergent
adverse events related to weight) relative to those patients who were
randomized to the standard intervention, but none of these differ-
ences was statistically significant.
To put the current findings into context, results of weight miti-
gation programs are typically modest at best, particularly when the
FIG. 3. Percentage of patients in the standard and intense behavioral weight counseling intervention groups with potentially clinically
significant increases in weight at any time and at endpoint.
FIG. 4. Mean changes in CGI-S for the total group of patients and by disease state (MMRM analysis). CGI-S, Clinical Global
Impression–Severity; MMRM, mixed model repeated measures; N, number of patients.
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FIG. 5. Mean changes in symptom ratings over time for patients receiving a standard or intense behavioral weight counseling
intervention (MMRM analysis). (a) Patients with schizophrenia, as rated on the BPRS-C. (b) Patients with bipolar disorder, as rated on
the YMRS. BPRS-C, Brief Psychiatric Rating Scale for Children; LS, least squares; MMRM, mixed model repeated measures; N,
number of patients; YMRS, Young Mania Rating Scale. *p< 0.05, **p< 0.01.
Table 2. Treatment-Emergent Adverse Events in ‡5% of All Patients, by Weight Intervention Group
All patients
(N = 203), n (%)
Standard group
(n= 102), n (%)
Intense group
(n= 101), n (%) p-Valuea
Any adverse event 162 (79.8) 81 (79.4) 81 (80.2) >0.999
Weight increased 52 (25.6) 31 (30.4) 21 (20.8) 0.148
Somnolence 43 (21.2) 19 (18.6) 24 (23.8) 0.395
Headache 39 (19.2) 19 (18.6) 20 (19.8) 0.860
Increased appetite 29 (14.3) 16 (15.7) 13 (12.9) 0.689
Nasopharyngitis 25 (12.3) 14 (13.7) 11 (10.9) 0.670
Blood insulin increased 17 (8.4) 10 (9.8) 7 (6.9) 0.614
Fatigue 15 (7.4) 9 (8.8) 6 (5.9) 0.593
Blood creatine phosphokinase
increased
12 (5.9) 7 (6.9) 5 (5.0) 0.767
Sedation 11 (5.4) 8 (7.8) 3 (3.0) 0.214
Vomiting 11 (5.4) 7 (6.9) 4 (4.0) 0.537
ap-Values are based on a Fisher exact test comparing two intervention groups.
N, total number of patients; n, number of affected patients.
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Table 3. Mean Changes from Baseline to Endpoint in Laboratory Analytes, Electrocardiograms,
and Blood Pressure by Weight Intervention Group (Last Observation Carried Forward)
Analyte
Standard group
(N = 102),
LS mean change (SE)
Intense group
(N = 101),
LS mean change (SE) p-Valuea
Hepatic laboratory measures ALT (U/L) 5.6 (1.8) 2.0 (1.8) 0.158
AST (U/L) 2.3 (1.0) 0.2 (1.0) 0.121
GGT (U/L) 3.4 (1.6) 0.1 (1.6) 0.136
Total bilirubin (umol/L) -1.1 (0.3) -1.4 (0.3) 0.410
Metabolic laboratory measures
(fasting)
Glucose (mmol/L) 0.1 (0.1) 0.1 (0.1) 0.724
Total cholesterol (mmol/L) 0.04 (0.1) -0.02 (0.1) 0.486
HDL cholesterol (mmol/L) -0.1 (0.02) -0.1 (0.02) 0.206
LDL cholesterol (mmol/L) 0.1 (0.1) 0.0 (0.1) 0.390
Triglycerides (mmol/L) 0.3 (0.1) 0.4 (0.1) 0.279
Endocrine laboratory measures Insulin (lIU/mL) 5.0 (2.4) 7.3 (2.4) 0.489
Prolactin (lg/L) -1.7 (1.1) -0.6 (1.1) 0.501
Hematologic laboratory measures Leukocytes (bill/L) -0.1 (0.2) -0.3 (0.2) 0.560
Neutrophils (bill/L) -0.2 (0.2) -0.4 (0.2) 0.322
Electrocardiogram Heart rate (bpm) 7.7 (1.3) 1.3 (1.3) <0.001
QTcF (milliseconds) 0.9 (1.6) 2.0 (1.6) 0.635
Blood pressure Supine systolic (mm Hg) 2.5 (1.1) 0.5 (1.1) 0.185
Supine diastolic (mm Hg) 2.4 (0.8) -0.4 (0.8) 0.017
Standing systolic (mm Hg) 3.7 (1.0) 0.6 (1.0) 0.031
Standing diastolic (mm Hg) 1.0 (0.9) -0.2 (0.9) 0.318
aBetween intervention group p-values for LS mean changes.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; LS, least squares; LOCF, last observation carried forward; QTcF, Fridericia-corrected QT interval; SE, standard error.
FIG. 6. Mean changes over time in select laboratory analytes for the total group of patients (MMRM analysis). MMRM, mixed model
repeated measures.
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intervention is of a counseling or educational nature and does not
require actual dieting or exercise but only counsels toward it (Poulin
et al. 2007). Moreover, not all such programs in adults have resulted
in statistically significant differences in weight, even when a multi-
modal approach was used (Usher et al. 2013; Cordes et al. 2014).
Systematic reviews of childhood obesity prevention programs in the
general population of overweight children found that none of the
home-based programs resulted in change in weight-related outcomes
(Showell et al. 2013) and few of the community-based programs
resulted in such changes (Bleich et al. 2013). Programs that were
more successful were for younger aged children and included a
school-based component (Bleich et al. 2013).
With respect to programs similar to those of the present study but
done in adults, Daumit et al. (2013) conducted a behavioral weight
intervention versus a negative control intervention in mentally ill
adults (predominantly patients with schizophrenia and bipolar dis-
order). The mean difference in weight change between the behavioral
weight intervention versus a negative control intervention group was
-1.5, -2.5, and -3.2 kg, at 6, 12, and 18 months, respectively. The
magnitude of 1-year difference between groups in that adult study
(2.5 kg) is thus similar to the magnitude of difference in the present
adolescent study (2.42 kg). Daumit et al. (2013) considered the ob-
served weight differences to be modest but clinically relevant.
Overall safety and tolerability
Considering the long-term safety and tolerability findings for
olanzapine across the total group of patients, results were generally
consistent with the known profile of olanzapine in adolescent pa-
tients observed in previous studies (Kryzhanovskaya et al. 2009b),
with some differences that could be attributed to the longer duration
of the current study and/or to the use of the behavioral weight
intervention. Although patients in the current study could receive
treatment with olanzapine for up to 52 weeks, the maximum du-
ration of any of the pooled trials in the Kryzhanovskaya et al.
(2009b) database was 32 weeks. Otherwise, the two populations
were comparable in terms of demographics, disease state compo-
sition, and olanzapine dosing.
Changes in weight and BMI were in line with the Kryzhanovskaya
et al. (2009b) results, although they were slightly higher in the
standard group at the end of 52 weeks relative to the other studies’ 32-
week result, which was consistent with longer treatment exposure.
The most notable difference was that patients in the current study
showed an overall mean decrease in prolactin from baseline, with
fewer patients developing treatment-emergent abnormally high
prolactin compared with previous adolescent olanzapine studies
(Kryzhanovskaya et al. 2009b). However, the overall visit-wise
pattern of mean changes in prolactin appeared consistent with the
pattern observed in the previous studies.
In the current study, only five patients experienced adverse events
that could have been related to changes in prolactin (two cases of
amenorrhea, one case of breast pain and acne, and one case of dys-
menorrhea), all of which were rated as mild in severity. In both the
current study and the previous studies, prolactin levels peaked at week
6 and decreased thereafter (Kryzhanovskaya et al. 2009b), although in
the current study, the prolactin levels continued to decrease below
baseline levels on average. No apparent explanation for this differ-
ence from previous studies could be found because baseline prolactin
levels and previous medication usage were similar across trials.
Disease state effectiveness
Although the current study was an open-label, uncontrolled study,
results are supportive of the effectiveness of olanzapine in the acute
and long-term treatment of adolescents with schizophrenia or bipolar
I disorder (manic or mixed episodes). All measures of clinical dis-
ease state effectiveness demonstrated significant improvement from
baseline as early as 3–4 days of treatment, with improvements
continuing for the remainder of the 52-week trial. Results were
comparable to those from the acute and open-label extension phases
of a prior study of olanzapine in adolescents with bipolar mania
(Tohen et al. 2007; McCormack 2010), as well as of a prior study of
olanzapine in adolescents with schizophrenia (Kryzhanovskaya et al.
2009a; McCormack 2010).
Interestingly, patients with bipolar disorder assigned to the in-
tense intervention showed somewhat less improvement in their
FIG. 7. Percentage of all patients with potentially clinically significant changes in select laboratory analytes at any time and at
endpoint. Potentially clinically significant definitions: fasting glucose ‡7 mmol/L following baseline of <5.6 mmol/L; fasting triglyc-
erides ‡1.5 mmol/L following baseline of <1.0 mmol/L; total fasting cholesterol ‡5.2 mmol/L following baseline of <4.4 mmol/L;
fasting LDL ‡3.4 mmol/L following baseline of <2.8 mmol/L; fasting HDL <0.9 mmol/L following baseline of ‡0.9 mmol/L; prolactin
>20 ng/mL for males or >29 ng/mL for females (ADA and NCEP criteria effective 2001). There were no significant differences between
the standard and intense intervention groups in categorical metabolic or prolactin changes at any time or at endpoint. ADA, American
Diabetes Association; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NCEP, National Cholesterol Education Program.
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symptom scores and were also more likely to have exacerbated
symptoms than those assigned to the standard weight intervention.
In contrast, no significant difference between the weight inter-
vention groups with respect to schizophrenia disease state effec-
tiveness was observed. Although there is no clear explanation for
this finding, one possibility is that patients with a mood disorder
and depressive tendencies may have been more likely to perceive
the intense intervention as aversive or stressful, with a perceived
focus on body image and implied expectations, thus possibly in-
terfering with psychological symptom improvements due to certain
disease characteristics, such as low self-esteem (Pavlickova et al.
2013). Another possibility was whether the increased focus on
weight may have resulted in greater self-dissatisfaction in the pa-
tients with bipolar disorder, which in turn may have led to poorer
treatment compliance in some patients in an attempt to minimize
weight gain and could then have affected treatment effectiveness.
Limitations
There are several limitations to the current study. With regard to
disease state effectiveness, the open-label uncontrolled design limits
the ability to draw strong conclusions about effectiveness. Never-
theless, this more naturalistic design is appropriate for the long-term
evaluation of a medication and provides results that may be more
generalizable to standard clinical practice. With regard to the be-
havioral weight intervention, it is important to acknowledge that the
interventions were office-based counseling programs that did not
require actual changes in patients’ diet and exercise behaviors. Al-
though patients were to keep track of their nutritional intake and
physical activity in daily logs, these data were not formally collected
for data analysis, and no information was collected from parents or
caregivers to attempt to quantify patients’ actual level of adherence
to the recommendations from the counseling sessions.
Other limitations include the baseline differences between the
disease state populations and the possible confounding of disease
state and geographical region. The patients with bipolar disorder
were heavier at baseline and more likely to have a family history of
obesity and metabolic disorders. At the same time, there was sig-
nificant overlap between disease state and region as most of the
patients with bipolar disorder were from the United States. Thus, it
is difficult to determine whether differences between the disease
state groups can be attributed to the disease state or to cultural
differences between regions. Overall, those comparisons should not
be made as the study was not designed for comparisons between
disease states but between weight interventions.
Finally, there was a notably high study discontinuation rate
observed (59.6%) in the current study. Although this rate is gen-
erally consistent with what has been observed in other studies of
antipsychotic usage in children and adolescents—for example,
Noguera et al. (2013) report a 1-year discontinuation rate of 59.1%
in their sample of 9- to 17-year-old first episode psychosis patients
treated with an antipsychotic—this high discontinuation could be
considered a limitation when interpreting the long-term study re-
sults. Although the statistical methods used in the current analyses
do account for patient discontinuation over time, it is important to
acknowledge that large amounts of missing data may challenge
these assumptions.
Conclusions
Tolerability and safety results of the current study were gener-
ally similar to those of previous adolescent studies, although
changes in prolactin and hepatic analytes were less notable. No new
safety signals were identified during this long-term study. Thus, the
findings from this study do not change the overall benefit–risk
profile of olanzapine in adolescents. Because the early onset of
schizophrenia or bipolar disorder is frequently associated with a
more severe course and poorer prognosis, olanzapine remains an
important treatment option for adolescents with schizophrenia or
bipolar disorder with manic or mixed episodes. The overall benefit–
risk profile in this patient population thus remains positive.
With regard to the benefit–risk profile of the standard and intense
behavioral weight interventions, results of this study did not dem-
onstrate a statistically significant difference between the two in-
terventions. Small but generally consistent numeric differences
between the groups suggest that individual patients may have gained
some benefit from the program. There appeared to be little safety risk
to using the program, although there was less improvement of psy-
chiatric state in the patients with bipolar disorder who were exposed
to the intense intervention. Thus, as implemented in the current
study, the overall benefit–risk profile for the weight intervention
program appears neutral in this population.
Results of the current study extend the data on olanzapine in
adolescents to 52-week treatment/observations and offer further
supportive evidence of both the acute and long-term effectiveness
of olanzapine in the treatment of schizophrenia and bipolar and
mixed mania in adolescents. This benefit must be weighed against
the risks observed in adolescent patients treated with olanzapine,
including weight gain and metabolic changes. It is recommended
that all patients treated with olanzapine receive regular monitoring
of weight, lipids, and glucose to help manage these risks.
Clinical Significance
The tolerability and safety of olanzapine for up to 52 weeks in
patients aged 13–17 years diagnosed with schizophrenia or bipolar
I disorder were generally similar to that observed previously in
adolescent patients treated for up to 32 weeks with olanzapine. The
most notable difference was that patients in the current study
showed an overall mean decrease in prolactin from baseline to
endpoint, with fewer patients developing treatment-emergent ab-
normally high prolactin compared with previous adolescent olan-
zapine studies. No statistically significant differences in BMI or
other weight-related changes were observed between standard and
intense weight intervention, although small numerical differences
were generally observed in favor of the intense intervention.
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